Publications

Sanchez JR 2nd, Liu C, Pawar V, Huang Y, Diaz-Rohena D, Singh J, Koppikar P, Lai TH, St John L, Puduvalli V, Molldrem J, Thandapani P, Jain N, Lapalombella R, Sampath D. NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. Leuk Lymphoma. 2026 Jan;67(1):97-107. doi: 10.1080/10428194.2025.2571199. Epub 2025 Dec 16. PMID: 41401031.

Freitas-Cortez MA, Masrorpour F, Jiang H, Mahmud I, Lu Y, Huang A, Duong LK, Wang Q, Voss TA, Kettlun Leyton CS, Wei B, Chan WK, Lin K, Zhang J, Tsouko E, Ganjoo S, Barsoumian HB, Riad TS, Hu Y, Leuschner C, Puebla-Osorio N, Wang J, Hu J, Davies MA, Puduvalli VK, Billon C, Burris TP, Lorenzi PL, Gan B, Welsh JW. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Mol Cancer. 2025 Feb 3;24(1):40. doi: 10.1186/s12943-024-02198-2. PMID: 39901247; PMCID: PMC11789333.

Strauss JD, Gilbert MR, Mehta M, Li A, Zhou R, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME. Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 7;27(3):767-778. doi: 10.1093/neuonc/noae234. PMID: 39549280; PMCID: PMC11889712.

Rehman S, Ikram M, Khan A, Khan A, Farzia, Khan R, Sinnokrot MO, Puduvalli VK, Jadoon A. Triethylammonium Salts of Dicoumarol: Synthesis, Characterization, Human Antiglioblastoma, Antimicrobial and Antioxidant Studies. Cell Biochem Biophys. 2025 Mar;83(1):999-1008. doi: 10.1007/s12013-024-01532-1. Epub 2024 Sep 22. PMID: 39306823.

Fleming JL, Pugh SL, Chang SM, McElroy JP, Becker AP, Aldape KD, Shih HA, Ashby LS, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Puduvalli VK, Robins HI, Werner-Wasik M, Mehta M, Chakravarti A. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2025 Mar 29:S0360-3016(25)00284-6. doi: 10.1016/j.ijrobp.2025.03.043. Epub ahead of print. PMID: 40164352.

Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, Couturier C, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D, GBM TeamLab, Puduvalli VK, Huse J, Beroukhim R, Kim BYS, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Chiocca EA, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nat Commun. 2025 Apr 28;16(1):3957. doi: 10.1038/s41467-025-58452-8. PMID: 40295505; PMCID: PMC12037860.

Zhao B, Cho CY, Ye L, Keal T, Mitchell T, Martin-Barrio I, Faraj CA, Unal M, Alsing J, Lawson NM, Kim ER, Chavez F, Rangel KM, Singh SK, McCarthy JH, Ashley DM, Yung WKA, Puduvalli V, Nir G, Weinberg JS, Wang L, Ligon KL, Genovese G, Loo PV, Futreal PA, Huse JT, Dixon JR, Lang FF, Akdemir KC. Oncogenic drivers shape the tumor microenvironment in human gliomas. bioRxiv [Preprint]. 2025 May 21:2025.05.16.654515. doi: 10.1101/2025.05.16.654515. PMID: 40475555; PMCID: PMC12139865.

Dasgupta P, Puduvalli VK. Diversity of metabolic features and relevance to clinical subtypes of gliomas. Semin Cancer Biol. 2025 Jul;112:126-134. doi: 10.1016/j.semcancer.2025.03.008. Epub 2025 Apr 5. PMID: 40194749.

Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2025 Sep;31(9):3204. doi: 10.1038/s41591-025-03895-1. Erratum for: Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. PMID: 40691367; PMCID: PMC12443589.

Garcia CR, Highsmith K, Knight S, Andrade IP, Leung CH, Puduvalli V, Kamiya-Matsuoka C. Single center experience of IDH inhibitors in recurrent high-grade gliomas. J Neurooncol. 2025 Nov;175(2):837-844. doi: 10.1007/s11060-025-05183-x. Epub 2025 Aug 1. PMID: 40748516.

Rock V, Ahluwalia MS, Anthony M, Arons D, Arzbaecher J, Dunbar E, Fraher C, Freund M, Gondi V, Khanuja S, Leach D, Loughan AR, Musella A, Oliver K, Paabo K, Puduvalli VK, Shaffer GD, Thomas AA, Wallgren K, Wefel JS, Yu JS, Zada G, Willmarth N, DeVitto R. Guiding principles for adult CNS tumor treatment programs. Neurooncol Adv. 2025 Aug 4;7(1):vdaf169. doi: 10.1093/noajnl/vdaf169. PMID: 40980442; PMCID: PMC12448407.

Jones G, Anderson JL, Nguyen PTT, Gleber-Netto FO, Hwang WL, Puduvalli VK, Monje M, Amit M. Novel approaches to clinical trial design in cancer neuroscience. Neuron. 2025 Sep 3;113(17):2791-2813. doi: 10.1016/j.neuron.2025.08.015. PMID: 40907474; PMCID: PMC12435926.

Goethe EA, Alfattal R, Srinivasan S, Dasgupta P, Puduvalli V, Weathers SP, Ballester LY, Weinberg JS, Prabhu S, Ferguson SD, Gubbiotti MA. High-grade glioma with pleomorphic and pseudopapillary features: a single-institution series of three cases. Acta Neuropathol Commun. 2025 Aug 18;13(1):176. doi: 10.1186/s40478-025-02097-7. PMID: 40826136; PMCID: PMC12363008.

Ling AL, Gantchev J, Prabhu MC, Basu S, Ahn R, D'Souza A, Masud N, Ball A, Nikas O, Villa GR, Regan MS, Baquer G, Ayoub G, Whittaker CA, Abou-Mrad Z, Santos A, Couturier CP, Elharouni D, Vogelzang J, Yu KKH, Chen H, He Z, Jiang W, Lucas CH, Sax HE, Lang FF, Puduvalli VK, Tabar V, W Brennan C, Boire A, Holdhoff M, Bettegowda C, Cima M, Solomon IH, Yuan Y, Tak PP; Accelerating GBM Therapies TeamLab; Sharma P, White FM, Ligon KL, Agar NYR, Reardon DA, Oliveira G, Chiocca EA. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Sci Transl Med. 2025 Oct 8;17(819):eadv2881. doi: 10.1126/scitranslmed.adv2881. Epub 2025 Oct 8. PMID: 41061048.

Dasgupta P, Dagher SA, Chi X, Soomro Z, Bhat S, Campbell E, Wintermark M, Puduvalli VK, Lin R, Chen MM, Majd NK. Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype. J Neurooncol. 2025 Oct 16;176(1):19. doi: 10.1007/s11060-025-05285-6. PMID: 41099968.

Msherghi A, Wong F, Xu G, Mawlawi O, Elhadi M, Alsharedi M, Salim HA, Alizada S, Ray WJ, Puduvalli VK, Wintermark M. ¹⁸F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control Study. J Nucl Med. 2025 Dec 3;66(12):1883-1890. doi: 10.2967/jnumed.125.270661. PMID: 41101978

Kotecha R, Schiff D, Chakravarti A, Fleming JL, Brown PD, Puduvalli VK, Vogelbaum MA, Gondi V, Gallus M, Okada H, Mehta MP. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. J Clin Oncol. 2024 Jul 20;42(21):2588-2598. doi: 10.1200/JCO.23.02195. Epub 2024 Jun 4. PMID: 38833641; PMCID: PMC11283772.

Lim-Fat MJ, Wen PY, Touat M, Puduvalli VK, Iorgulescu JB. MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma. Neuro Oncol. 2024 Sep 11:noae157. doi: 10.1093/neuonc/noae157. Epub ahead of print. PMID: 39277807.

Shatara M, Blue M, Stanek J, Liu YA, Prevedello DM, Giglio P, Puduvalli VK, Gardner SL, Allen JC, Wong KK, Nelson MD, Gilles FH, Adams RH, Pauly J, O'Halloran K, Margol AS, Dhall G, Finlay JL. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors. Neurooncol Pract. 2023 Oct 14;11(2):188-198. doi: 10.1093/nop/npad067. PMID: 38496907; PMCID: PMC10940828.

Sharma P, Puduvalli VK. Protocol for real-time assessment of mitochondrial and glycolytic ATP production in patient-derived glioma stem-like cells. STAR Protoc. 2024 Sep 20;5(3):103159. doi: 10.1016/j.xpro.2024.103159. Epub 2024 Jun 27. PMID: 38941182; PMCID: PMC11261133.

Rehman S, Ikram M, Khan A, Khan A, Farzia, Khan R, Sinnokrot MO, Puduvalli VK, Jadoon A. Triethylammonium Salts of Dicoumarol: Synthesis, Characterization, Human Antiglioblastoma, Antimicrobial and Antioxidant Studies. Cell Biochem Biophys. 2024 Sep 22. doi: 10.1007/s12013-024-01532-1. Epub ahead of print. PMID: 39306823.

Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O'Brien BJ, Majd NK, Loghin ME, Patel CB, Weathers SP, Puduvalli VK, Kamiya-Matsuoka C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study. Neurooncol Pract. 2024 Apr 8;11(4):475-483. doi: 10.1093/nop/npae029. PMID: 39006516; PMCID: PMC11241387.

Strauss JD, Gilbert MR, Mehta M, Li A, Ms RZ, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME. Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2024 Nov 16:noae234. doi: 10.1093/neuonc/noae234. Epub ahead of print. PMID: 39549280.

Rixe O, Villano JL, Wesolowski R, Noonan AM, Puduvalli VK, Wise-Draper TM, Curry R 3rd, Yilmaz E, Cruze C, Ogretmen B, Tapolsky G, Takigiku R. A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas. Clin Cancer Res. 2024 Nov 15;30(22):5053-5060. doi: 10.1158/1078-0432.CCR-24-1721. PMID: 39264252.

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. PMID: 37272516; PMCID: PMC11445763.

Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv. 2023 Feb 23;5(1):vdad009. doi: 10.1093/noajnl/vdad009. PMID: 36968288; PMCID: PMC10034917.

Zhong S, Yang W, Zhang Z, Xie Y, Pan L, Ren J, Ren F, Li Y, Xie H, Chen H, Deng D, Lu J, Li H, Wu B, Chen Y, Peng F, Puduvalli VK, Sai K, Li Y, Cheng Y, Mou Y. Association between viral infections and glioma risk: a two-sample bidirectional Mendelian randomization analysis. BMC Med. 2023 Dec 5;21(1):487. doi: 10.1186/s12916-023-03142-9. PMID: 38053181; PMCID: PMC10698979.

Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. Epub 2023 May 15. PMID: 37188783; PMCID: PMC10287560.

Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D; GBM TeamLab; Puduvalli VK, Huse J, Beroukhim R, Kim YSB, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Antonio Chiocca E, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Investigative needle core biopsies for multi-omics in Glioblastoma. medRxiv [Preprint]. 2023 Dec 31:2023.12.29.23300541. doi: 10.1101/2023.12.29.23300541. PMID: 38234840; PMCID: PMC10793534.

Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma. Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. PMID: 36968138; PMCID: PMC10035510.

Harrison RA, Majd NK, Johnson MO, Urbauer DL, Puduvalli V, Khasraw M. Characterization of industry relationships in oncology. Cancer. 2023 Sep 15;129(18):2848-2855. doi: 10.1002/cncr.34852. Epub 2023 May 25. PMID: 37227811.

Bartkowiak T, Brockman AA, Mobley BC, Harmsen H, Moots P, Merrell R, Johnson DB, Thompson RC, Puduvalli VK, Ihrie RA. Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastoma. medRxiv [Preprint]. 2023 Dec 26:2023.12.08.23299732. doi: 10.1101/2023.12.08.23299732. PMID: 38234786; PMCID: PMC10793510.

Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos J, Shukla S, Puduvalli V, Woyach J, Lapalombella R, Blachly J, Byrd JC, Sampath D. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. Blood Adv. 2023 Jun 27;7(12):2897-2911. doi: 10.1182/bloodadvances.2022007998. PMID: 36287107; PMCID: PMC10285551.

Gregory TA, Williford GL, Maronge JM, Alfaro K, Fuller GN, de Groot J, Puduvalli VK, Ballester LY, Majd NK. An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas. Neuro Oncol. 2023 Apr 6;25(4):808-809. doi: 10.1093/neuonc/noad007. PMID: 36723868; PMCID: PMC10076931.

Khan A, Ikram M, Rehman S, Khan R, Puduvalli VK, Jadoon A, Khan M, Alasmari F, AlAsmari AF. Triethylammonium salt of a synthesized dicoumarol: Structural insight and human anti-glioblastoma activities. Heliyon. 2023 Jun 25;9(7):e17601. doi: 10.1016/j.heliyon.2023.e17601. PMID: 37456028; PMCID: PMC10338367.

Shatara M, Blue M, Stanek J, Liu YA, Prevedello DM, Giglio P, Puduvalli VK, Gardner SL, Allen JC, Wong KK, Nelson MD, Gilles FH, Adams RH, Pauly J, O'Halloran K, Margol AS, Dhall G, Finlay JL. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors. Neurooncol Pract. 2023 Oct 14;11(2):188-198. doi: 10.1093/nop/npad067. PMID: 38496907; PMCID: PMC10940828.

Liang J, Fang D, Gumin J, Najem H, Sooreshjani M, Song R, Sabbagh A, Kong LY, Duffy J, Balyasnikova IV, Pollack SM, Puduvalli VK, Heimberger AB. A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin. Cancers (Basel). 2023 Feb 8;15(4):1085. doi: 10.3390/cancers15041085. PMID: 36831427; PMCID: PMC9953964.

Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Apr 13;5(1):vdad032. doi: 10.1093/noajnl/vdad032. PMID: 37114244; PMCID: PMC10129387.

Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 Feb 15;28(4):585-593. doi: 10.1158/1078-0432.CCR-21-2681. PMID: 34561270; PMCID: PMC9306329.

Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022 Jun 1;28(11):2270-2277. doi: 10.1158/1078-0432.CCR-21-2664. PMID: 35344029; PMCID: PMC9167702.

Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2022 Feb 1;24(2):229-244. doi: 10.1093/neuonc/noab175. PMID: 34260721; PMCID: PMC8804900.

Xu J, Wu PJ, Lai TH, Sharma P, Canella A, Welker AM, Beattie CE, Elder JB, Easley M, Lonser R, Jacob NK, Pietrzak M, Timmers CM, Lang F, Sampath D, Puduvalli VK. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy. Clin Cancer Res. 2022 May 2;28(9):1979-1990. doi: 10.1158/1078-0432.CCR-20-0468. PMID: 35140124; PMCID: PMC9064967.

Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J. Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neurooncol Adv. 2021 Dec 24;4(1):vdab186. doi: 10.1093/noajnl/vdab186. PMID: 35088051; PMCID: PMC8788017.

Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, Grecula J, Welliver M, Williams T, Elder JB, Raval R, Blakaj D, Haglund K, Bazan J, Kendra K, Arnett A, Beyer S, Liebner D, Giglio P, Puduvalli V, Chakravarti A, Wuthrick E. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022 May;170:21-26. doi: 10.1016/j.radonc.2022.03.016. Epub 2022 Mar 31. PMID: 35367525.

Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv. 2022 Aug 20;4(1):vdac129. doi: 10.1093/noajnl/vdac129. PMID: 36128585; PMCID: PMC9476222.

Rayi A, Alnahhas I, Ong S, Giglio P, Puduvalli VK. Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 Oct 6;22(11):105. doi: 10.1007/s11864-021-00901-9. PMID: 34613491.

Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021 Jul;9(7):e002459. doi: 10.1136/jitc-2021-002459. PMID: 34215688; PMCID: PMC8256733.

Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J. Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neurooncol Adv. 2021 Dec 24;4(1):vdab186. doi: 10.1093/noajnl/vdab186. PMID: 35088051; PMCID: PMC8788017.

Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, Wong ET, Glas M. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Front Oncol. 2021 May 7;11:679702. doi: 10.3389/fonc.2021.679702. PMID: 34026655; PMCID: PMC8139188.

Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V. Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis. Neurooncol Adv. 2021 Jul 10;3(1):vdab095. doi: 10.1093/noajnl/vdab095. Erratum for: Neurooncol Adv. 2020 Oct 30;2(1):vdaa082. doi: 10.1093/noajnl/vdaa082. PMID: 34258581; PMCID: PMC8272530.

Alnahhas I, Rayi A, Palmer JD, Raval R, Folefac E, Ong S, Giglio P, Puduvalli V. The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis: a retrospective cohort study. Neurooncol Pract. 2020 Oct 17;8(1):75-80. doi: 10.1093/nop/npaa067. PMID: 33664972; PMCID: PMC7906267.

Lee EQ, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, Chang SM, de Groot JF, Galanis E, Hassan I, Kalidas C, Khasraw M, Kvedar JC, Lassman AB, Puduvalli V, Sahebjam S, Schwamm LH, Tamir S, Welch M, Yung WKA, Zadeh G, Arons D, Wen PY. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol. 2021 Aug 2;23(8):1252-1260. doi: 10.1093/neuonc/noab082. PMID: 33822177; PMCID: PMC8083574.

Alnahhas I, Rayi A, Guillermo Prieto Eibl MDP, Ong S, Giglio P, Puduvalli V. Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH wt glioblastoma. Neurooncol Adv. 2021 Oct 1;3(1):vdab127. doi: 10.1093/noajnl/vdab127. PMID: 34667950; PMCID: PMC8519397.

Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM. Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. Eur J Breast Health. 2021 Oct 4;17(4):371-377. doi: 10.4274/ejbh.galenos.2021.2021-4-10. PMID: 34651117; PMCID: PMC8496125.

Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021 Oct 2;3(1):vdab141. doi: 10.1093/noajnl/vdab141. PMID: 34693288; PMCID: PMC8528265.

Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jun 22;3(1):vdab079. doi: 10.1093/noajnl/vdab079. PMID: 34377987; PMCID: PMC8350154.

Cheng X, Geng F, Pan M, Wu X, Zhong Y, Wang C, Tian Z, Cheng C, Zhang R, Puduvalli V, Horbinski C, Mo X, Han X, Chakravarti A, Guo D. Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress. Cell Metab. 2020 Aug 4;32(2):229-242.e8. doi: 10.1016/j.cmet.2020.06.002. Epub 2020 Jun 18. PMID: 32559414; PMCID: PMC7415721.

Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Nov2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052. PMID: 33152694.

Balogun J, Haynes C, Lwin Z, Nduom E, Puduvalli V, Venere M, Zadeh G. SNO 25th anniversary history series: Providing a global platform for communication and exchange in neuro-oncology. Neuro Oncol. 2020 Nov 26;22(11):1551-1552. doi: 10.1093/neuonc/noaa219. PMID: 32995879; PMCID: PMC7690359.

Venere M, Zadeh G, Puduvalli V, Haynes C. The Society for Neuro-Oncology: 20/20 vision for the future. Neuro Oncol. 2020 Apr 15;22(4):435-436. doi: 10.1093/neuonc/noaa043. PMID: 32095809; PMCID: PMC7158644.

Venere M, Zadeh G, Puduvalli V, Haynes C. Celebrating SNO's official journal, Neuro-Oncology. Neuro Oncol. 2020 May 15;22(5):585-586. doi: 10.1093/neuonc/noaa070. PMID: 32415306; PMCID: PMC7229250.

Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th anniversary history series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances. Neuro Oncol. 2020 Jun 9;22(6):739-740. doi: 10.1093/neuonc/noaa108. PMID: 32518956; PMCID: PMC7282891.

Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th anniversary history series: Investing in the membership of the Society for Neuro-Oncology. Neuro Oncol. 2020 Jul 7;22(7):897-898. doi: 10.1093/neuonc/noaa129. PMID: 32479630; PMCID: PMC7339883.

Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020 Oct 30;2(1):vdaa082. doi: 10.1093/noajnl/vdaa082. PMID: 33150334; PMCID: PMC7596890.

Alnahhas I, LaHaye S, Giglio P, Mardis E, Puduvalli V. An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma. Neurooncol Adv. 2020 Nov 16;2(1):vdaa117. doi: 10.1093/noajnl/vdaa117. PMID: 33880446; PMCID: PMC8044669.

Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th anniversary history series: Ancillary and satellite meetings of the Society for Neuro-Oncology. Neuro Oncol. 2020 Sep 29;22(9):1231-1232. doi: 10.1093/neuonc/noaa211. PMID: 32991721; PMCID: PMC7523437.

Alnahhas I, Rayi A, Palmer JD, Raval R, Folefac E, Ong S, Giglio P, Puduvalli V. The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis: a retrospective cohort study. Neurooncol Pract. 2020 Oct 17;8(1):75-80. doi: 10.1093/nop/npaa067. PMID: 33664972; PMCID: PMC7906267.

Gatson NTN, Bross SP, Odia Y, Mongelluzzo GJ, Hu Y, Lockard L, Manikowski JJ, Mahadevan A, Kazmi SAJ, Lacroix M, Conger AR, Vadakara J, Nayak L, Chi TL, Mehta MP, Puduvalli VK. Early imaging marker of progressing glioblastoma: a window of opportunity. J Neurooncol. 2020 Jul;148(3):629-640. doi: 10.1007/s11060-020-03565-x. Epub 2020 Jun 29. PMID: 32602020.

Wang JL, Barth RF, Cavaliere R, Puduvalli VK, Giglio P, Lonser RR, Elder JB. Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. PLoS One. 2020 Dec 29;15(12):e0244383. doi: 10.1371/journal.pone.0244383. PMID: 33373402; PMCID: PMC7771668.

Alnahhas I, Rayi A, Thomas D, Ong S, Giglio P, Puduvalli V. False-positive 1p/19q Testing Results in Gliomas: Clinical and Research Consequences. Am J Clin Oncol. 2020 Nov;43(11):802-805. doi: 10.1097/COC.0000000000000755. PMID: 32889892.

Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 Oct 14;22(10):1505-1515. doi: 10.1093/neuonc/noaa062. PMID: 32166308; PMCID: PMC7686463.

Freeman T, Legasto CS, Schickli MA, McLaughlin EM, Giglio P, Puduvalli V, Gonzalez J. High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neurooncol Adv. 2020 Jun 29;2(1):vdaa077. doi: 10.1093/noajnl/vdaa077. PMID: 32715297; PMCID: PMC7372924.

Puduvalli V, Venere M, Haynes C, Zadeh G. SNO 25th anniversary history series: The SNO Annual Meeting - A nexus for science, collaboration and community. Neuro Oncol. 2020 Aug 17;22(8):1053-1055. doi: 10.1093/neuonc/noaa155. PMID: 32804242; PMCID: PMC7594569.